Beta Drugs valuation

·UnclassifiedChart ›
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
Price multiples — at each FY-end close
35.15×——
4.28×——
4.22×——
Enterprise multiples
4.64×——
22.31×——
27.77×——
Yield
2.8%——
−0.9%——
Reference — adjusted share basis
₹1,849.70——
₹52.62₹40.92₹41.85
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BETA₹1,849.70

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹1,875 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E——35.15
P/B——4.28
P/Sales——4.22
Enterprise Multiples
EV/Sales——4.64
EV/EBITDA——22.31
EV/EBIT——27.77
Yield
Earnings Yield %——2.84
FCF Yield %——-0.86
Reference — adjusted share basis
Price (FY-end close, adj.)——1,849.70
EPS (adj.)41.8540.9252.62
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.